Cargando…

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world

OBJECTIVES: The combination of immunotherapy and chemotherapy has shown great efficacy in stage IV non–small cell lung cancer (NSCLC) and is now widely used in clinical treatment strategy. This study retrospectively analyzed the efficacy and safety of neoadjuvant immunotherapy plus chemotherapy for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Min, Hang, Qingqing, Jiang, Haitao, Cai, Lei, Hu, Jinlin, Ying, Hangjie, Gu, Qing, Yu, Xiaofu, Liu, Jinshi, Lai, Xiaojing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877512/ https://www.ncbi.nlm.nih.gov/pubmed/36713546 http://dx.doi.org/10.3389/fonc.2022.1055610

Ejemplares similares

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Cardiac tamponade, a rare complication of gastric cardia cancer resection after neoadjuvant chemotherapy combined with immunotherapy: a case report and literature review
por: Du, Wei, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
por: Díaz-Redondo, Tamara, et al.
Publicado: (2019)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

Prognostic Value of Tumor Regression Grading in Patients Treated With Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer
por: Xie, Jian-Wei, et al.
Publicado: (2021)

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
por: Xu, Hao, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

A Novel Combined Nomogram Model for Predicting the Pathological Complete Response to Neoadjuvant Chemotherapy in Invasive Breast Carcinoma of No Specific Type: Real-World Study
por: Zhu, Xuelin, et al.
Publicado: (2022)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial
por: Newell, Marnie, et al.
Publicado: (2019)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer
por: He, Chaobin, et al.
Publicado: (2021)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

Machine Learning-Assisted Ensemble Analysis for the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
por: Huang, Yibao, et al.
Publicado: (2022)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
por: Yu, Yuanyuan, et al.
Publicado: (2021)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis
por: Cheng, Qingqing, et al.
Publicado: (2020)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
por: Vivarelli, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t05dp3du8anepba46v5qrpltdt